In PN21 (a pancreatic tumour), ON33 (a serous ovarian tumour), and BN16 (a TNBC tumour), EGFR/Notch-targeting bispecific antibodies demonstrated significant efficacy in combination with the PARP inhibitor talazoparib (Figure S8A). Here, PARP1 is linked to neoplasm.